Episode
Episode 71. Management of Newly Diagnosed Multiple Myeloma with Dr. Vincent Rajkumar
- Podcast
- Blood Cancer Talks
- Published
- May 19, 2026
- Duration seconds
- 3126
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/85832ee7
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-71-management-of-newly-diagnosed-multiple-myeloma-with-dr-vincent-rajkumar/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-71-management-of-newly-diagnosed-multiple-myeloma-with-dr-vincent-rajkumar.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode, Raj, Ashwin, and Eddie sit down with Dr. Vincent Rajkumar — Professor of Medicine at Mayo Clinic and Chair of the ECOG Myeloma Committee — for a clinically focused conversation on newly diagnosed multiple myeloma. Topics span baseline workup, risk stratification, induction selection, transplant timing, MRD-directed decision-making, and maintenance strategy. The episode closes with a discussion of Open Medicine, a new medical education platform, and Dr. Rajkumar's ongoing advocacy on drug pricing reform. KEY TOPICS DISCUSSED Baseline workup: 24-hour urine protein: It is important to obtain 24-hour urine protein with electrophoresis and immunofixation in all newly diagnosed patients — not for diagnosis, but to establish a baseline for long-term management and to distinguish M-protein from albuminuria. In patients where an FLC ratio ≥100 is the sole myeloma-defining criterion, a 24-hour urine Bence Jones protein ≥200 mg is part of the diagnostic threshold for treatment initiation. Myeloma cast nephropathy: when to biopsy: An involved FLC ≥50 mg/dL supports a presumptive diagnosis of cast nephropathy and treatment can begin without a kidney biopsy. Below this threshold — particularly if renal involvement is the sole myeloma-defining event — kidney biopsy is warranted to exclude light chain deposition disease, MPGN, or other unrelated disorders. It warrants aggressive early treatment (Dara-VCD or Dara-VD), starting even before bone marrow results are available when the diagnosis is clinically clear. Solitary plasmacytoma [with or without minimal bone marrow involvement]: Patients with ~10% clonal plasma cells technically meet criteria for myeloma, but management in this borderline zone warrants shared decision-making. Solitary plasmacytoma as sitting betwee…